Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions

Andrea R. Shiakolas, Kevin J. Kramer, Daniel Wrapp, Simone I. Richardson, Alexandra Schäfer, Steven Wall, Nianshuang Wang, Katarzyna Janowska, Kelsey A. Pilewski, Rohit Venkat, Robert Parks, Nelia P. Manamela, Nagarajan Raju, Emilee Friedman Fechter, Clinton M. Holt, Naveenchandra Suryadevara, Rita E. Chen, David R. Martinez, Rachel S. Nargi, Rachel E. Sutton, Julie E. Ledgerwood, Barney S. Graham, Michael S. Diamond, Barton F. Haynes, Priamvada Acharya, Robert H. Carnahan, James E. Crowe, Jr., Ralph S. Baric, Lynn Morris, Jason S. McLellan, Ivelin S. Georgiev

PII: S2666-3791(21)00156-7
DOI: https://doi.org/10.1016/j.xcrm.2021.100313
Reference: XCRM 100313
To appear in: Cell Reports Medicine

Received Date: 22 December 2020
Revised Date: 17 March 2021
Accepted Date: 18 May 2021

Please cite this article as: Shiakolas, A.R., Kramer, K.J., Wrapp, D., Richardson, S.I., Schäfer, A., Wall, S., Wang, N., Janowska, K., Pilewski, K.A., Venkat, R., Parks, R., Manamela, N.P., Raju, N., Fechter, E.F., Holt, C.M., Suryadevara, N., Chen, R.E., Martinez, D.R., Nargi, R.S., Sutton, R.E., Ledgerwood, J.E., Graham, B.S., Diamond, M.S., Haynes, B.F., Acharya, P., Carnahan, R.H., Crowe Jr., J.E., Baric, R.S., Morris, L., McLellan, J.S., Georgiev, I.S., Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions, Cell Reports Medicine (2021), doi: https://doi.org/10.1016/j.xcrm.2021.100313.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 The Author(s).
LIBRA-seq

donor PBMCs

SARS2 S
SARS S
MERS S
MERS S1
OC43 S
HKU1 S
ZM197
CZA97

CoV Cross-reactive Antibody Identification

Epitope Mapping

Functional Evaluation and

in vivo Prophylaxis Experiment
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions

Andrea R. Shiakolas, Kevin J. Kramer, Daniel Wrapp, Simone I. Richardson, Alexandra Schäfer, Steven Wall, Nianshuang Wang, Katarzyna Janowska, Kelsey A. Pilewski, Rohit Venkat, Robert Parks, Nelia P. Manamela, Nagarajan Raju, Emilee Friedman Fechter, Clinton M. Holt, Naveenchandra Suryadevara, Rita E. Chen, David R. Martinez, Rachel S. Nargi, Rachel E. Sutton, Julie E. Ledgerwood, Barney S. Graham, Michael S. Diamond, Barton F. Haynes, Priyamvada Acharya, Robert H. Carnahan, James E. Crowe Jr, D. Baric, Lynn Morris, Jason S. McLellan, Ivelin S. Georgiev, Michael S. Diamond, Barton F. Haynes, Priyamvada Acharya, Robert H. Carnahan, James E. Crowe Jr, D. Baric, Lynn Morris, Jason S. McLellan, Ivelin S. Georgiev

1 Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
2 Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
3 Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, 78712, USA
4 National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa; Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
5 Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27516, USA
6 Division of Structural Biology, Duke University School of Medicine, Durham, NC, 27710, USA
7 Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
8 Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA
These authors contributed equally.

*Corresponding author: ivelin.georgiev@vanderbilt.edu
SUMMARY

The continual emergence of novel coronavirus (CoV) strains, like SARS-CoV-2, highlights the critical need for broadly reactive therapeutics and vaccines against this family of viruses. From a recovered SARS-CoV donor sample, we identify and characterize a panel of six monoclonal antibodies that cross-react with CoV spike (S) proteins from the highly pathogenic SARS-CoV and SARS-CoV-2, and demonstrate a spectrum of reactivity against other CoV. Epitope mapping reveals that these antibodies recognize multiple epitopes on SARS-CoV-2 S, including the receptor binding domain, N-terminal domain, and S2 subunit. Functional characterization demonstrates that the antibodies mediate phagocytosis - and in some cases trogocytosis - but not neutralization in vitro. When tested in vivo in murine models, two of the antibodies demonstrate a reduction in hemorrhagic pathology in the lungs. The identification of cross-reactive epitopes recognized by functional antibodies expands the repertoire of targets for pan-coronavirus vaccine design strategies.
INTRODUCTION

The emergence of a novel coronavirus (CoV) SARS-CoV-2, the causative agent of COVID-19, has resulted in a worldwide pandemic, threatening the lives of billions and imposing an immense burden on healthcare systems and the global economy. SARS-CoV-2, the seventh coronavirus known to infect humans, is a member of the Betacoronavirus genus which includes the highly pathogenic SARS-CoV and MERS-CoV, as well as endemic variants HCoV-OC43 and HCoV-HKU1. Recent coronavirus outbreaks and the threat of future emerging zoonotic strains highlight the need for broadly applicable coronavirus therapeutic interventions and vaccine design approaches.

Coronaviruses utilize the homotrimeric Spike (S) protein to engage with cell-surface receptors and enter host cells. S consists of two functional subunits: S1 and S2. S1 facilitates attachment to target cells and is composed of the N-terminal domain (NTD) and the receptor-binding domain (RBD), whereas S2, which encodes the fusion peptide and heptad repeats, promotes viral fusion. To facilitate cell entry, human coronaviruses employ different host factors; however, SARS-CoV and SARS-CoV-2 both utilize the cell-surface receptor angiotensin converting enzyme 2 (ACE2). Additionally, SARS-CoV-2 S shares 76% amino acid identity with SARS-CoV S. Furthermore, S serves as a dominant antibody target and is a focus of countermeasure development for the treatment and prevention of COVID-19 infection. S proteins from the Betacoronavirus genus share multiple regions of structural homology and thus could serve as targets for a cross-reactive antibody response. Identifying cross-reactive antibody epitopes can inform rational design strategies for vaccines and therapies that target multiple highly pathogenic coronaviruses.

Numerous potent neutralizing antibodies against SARS-CoV-2 have been discovered, including multiple candidates currently in clinical trials or approved for emergency use for prophylactic
and acute treatment of COVID-19\textsuperscript{9–16}. Investigation of SARS-CoV-2/SARS-CoV cross-reactive antibodies has focused primarily on the RBD epitope, which has resulted in the identification of a number of SARS-CoV-2/SARS-CoV cross-reactive antibody candidates\textsuperscript{12,17,18}. However, the diversity of epitopes and functions beyond virus neutralization have not been extensively explored for cross-reactive antibodies\textsuperscript{19–21}. Evidence of Fc effector function contributing to protection \textit{in vivo} against SARS-CoV\textsuperscript{22} and SARS-CoV-2\textsuperscript{23} suggests that the role of antibodies beyond neutralization may be a crucial component of protection and an important consideration in vaccine design strategies for coronaviruses\textsuperscript{20,24–26}.

In this study, we investigated antibody cross-reactivity across the \textit{Betacoronavirus} genus at monoclonal resolution. To do this, we applied LIBRA-seq (Linking B Cell receptor to antigen specificity through sequencing\textsuperscript{27} to a recovered SARS-CoV donor sample from more than ten years after infection. We identified and characterized SARS-CoV-2/SARS-CoV cross-reactive human antibodies that target multiple, distinct structural domains of S, mediate phagocytosis and trogocytosis, and mitigate pathological burden \textit{in vivo}. A better understanding of the genetic features, epitope specificities, and functional characteristics of cross-reactive coronavirus antibodies may translate into strategies for current vaccine design efforts and additional measures to counteract potential future pandemic strains.

\textbf{RESULTS}

\textbf{LIBRA-seq Characterization of a SARS-CoV Recovered Donor}

To identify cross-reactive antibodies to multiple coronavirus antigens, LIBRA-seq was applied to a PBMC sample from a donor infected with SARS-CoV over ten years prior to sample collection. The antigen screening library consisted of eight oligo-tagged recombinant soluble antigens: six coronavirus trimer antigens (SARS-CoV-2 S, SARS-CoV S, MERS-CoV S, MERS-CoV S1 (with foldon domain), HCoV-OC43 S, HCoV-HKU1 S) and two HIV trimer antigens from strains
ZM197 and CZA97 as negative controls (Figure 1A). After the antigen screening library was mixed with donor PBMCs, antigen positive B cells were enriched by fluorescence activated cell sorting and processed for single-cell sequencing (Supplemental Figure 1A). After bioinformatic processing, we recovered 2625 cells with paired heavy/light chain sequences and antigen reactivity information (Supplemental Figure 1B), and from these cells, there were 2368 unique VDJ sequences. Overall, LIBRA-seq enabled rapid screening of PBMCs from a patient sample, with recovery of paired heavy/light chain sequences and antigen reactivity for thousands of B cells at the single-cell level.

Identification of SARS-CoV-2 and SARS-CoV Cross-reactive Antibodies

With a goal of identifying antibodies that were cross-reactive to multiple coronavirus S proteins, we prioritized lead candidates based on their sequence features and LIBRA-seq scores (Supplemental Figure 1C). We selected 15 antibody candidates that exhibited diverse sequence features and utilized a number of different variable genes for expression and characterization (Figure 1B, Supplemental Figure 1D). These antibodies displayed a broad range of percent identity to germline (83-98%) and a variety of CDRH3 and CDRL3 lengths (6-24 and 5-13 amino acids, respectively) (Supplemental Figure 1D). By ELISA, SARS-CoV-2 S and SARS-CoV S binding was confirmed for 6/15 of the tested antibodies (46472-1, 46472-2, 46472-3, 46472-4, 46472-6, and 46472-12), indicating LIBRA-seq could successfully identify SARS-CoV-2 reactive B cells, but also suggesting potential differences in antigen binding detection for primary B cells with a sequencing readout vs. recombinant IgG by ELISA (Figure 1C-D, Supplemental Figure 1E). Further, antibodies 46472-6 and 46472-12 bound to S proteins from endemic HCoV-OC43 and HCoV-HKU1, albeit generally at lower levels (Figure 1C-D, Supplemental Figure 1E). Although the six monoclonal antibodies showed reactivity by ELISA to the MERS-CoV antigen probe used in the LIBRA-seq screening library, antibody binding to other independent preparations of this protein was inconsistent, so MERS-CoV S reactivity could not be confirmed definitively (Supplemental Figure 1F-G). Overall, the
application of the LIBRA-seq technology enabled the identification of a panel of cross-reactive antibodies that recognize the S antigen from multiple coronaviruses.

**Cross-reactive Coronavirus Antibodies Target Diverse Epitopes on S**

To elucidate the epitopes targeted by the cross-reactive antibodies, we performed binding assays to various structural domains of S as well as binding-competition experiments. First, we assessed antibody binding to the S1 and S2 subdomains of SARS-CoV-2. Antibodies 46472-1, 46472-2, 46472-3, and 46472-4 bound to the S2 domain, whereas 46472-6 and 46472-12 recognized the S1 domain but targeted different epitopes, the NTD and RBD, respectively (Figure 2A-C, Supplemental Figure 2A-B). Although 46472-12 bound to the RBD, it did not compete with ACE2 for binding to SARS-CoV-2 S and showed partial competition with RBD-directed antibody CR3022 (Supplemental Figure 2C-D). To determine whether the antibodies targeted overlapping or distinct epitopes, we performed competition ELISA experiments and found that the S2-directed antibodies 46472-1, 46472-2, and 46472-4 competed for binding to S (Figure 2D). This pattern was observed for both SARS-CoV-2 and SARS-CoV S. Of note, this competition group did not include S2-directed antibody 46472-3, revealing the identification of multiple cross-reactive epitope targets on S2 (Figure 2D). Further, antibody binding was not affected by two glycan knockout mutants (N165A or N709A) or mannose competition (Supplemental Figure 2E-F). Lastly, we measured antibody autoreactivity, and found that with the exception of 46472-6 binding to Jo-1, none of the antibodies showed autoreactivity against the tested antigens (Figure 2E). Together, these data suggest that the identified cross-reactive antibodies are coronavirus-specific and target multiple, diverse epitopes on the S protein (Figure 2F).

**Functional Characterization of Cross-reactive Coronavirus Antibodies**

Next, we characterized our cross-reactive antibody panel for functional activity. Although none of the antibodies neutralized SARS-CoV or SARS-CoV-2 (Supplemental Figure 3A-B), all antibodies showed antibody-dependent cellular phagocytosis (ADCP) *in vitro* for SARS-CoV-2 S
(Figure 3A). In particular, the RBD-reactive antibody 46472-12 showed greater ADCP activity compared to the other cross-reactive antibodies and the SARS-CoV/SARS-CoV-2 cross-reactive RBD antibody control, CR302228 (Figure 3A, Supplemental Figure 3C). Further, we tested and confirmed ADCP activity against SARS-CoV for two antibodies that mediated the highest phagocytotic activity against SARS-CoV-2, 46472-4 and 46472-12, illustrating that these antibodies have cross-coronavirus phagocytic ability (Figure 3B, Supplemental Figure 3D).

We next tested the antibodies in a trogocytosis assay29 and found that four antibodies in our panel (46472-1, 46472-2, 46472-3, and 46472-4) mediated trogocytosis (Figure 3C, Supplemental Figure 3E). This warrants further investigation as this is the first description of trogocytosis performed by SARS-CoV-2 specific mAbs. Lastly, none of the antibodies promoted complement deposition (ADCD) (Figure 3D, Supplemental Figure 3F). Together, these results revealed different profiles of Fc effector functionality within the panel of cross-reactive antibodies.

Since non-neutralizing SARS-CoV-2 antibodies with Fc effector function activity have not been extensively characterized in vivo, these results prompted us to test antibodies 46472-4 and 46472-12 for prophylaxis in a murine infection model using a mouse-adapted virus strain (SARS-CoV-2 MA)30,31 at a non-lethal dose of 1x10³ PFU (Figure 4A). Although there were no differences in survival and viral load between experimental and control groups, the lung hemorrhage scores (see Methods) for 46472-4 and 46472-12 were similar to antigen-specific control CR3022, and all three groups were significantly lower than the scores for isotype control DENV-2D22 (p<0.01, ordinary one-way ANOVA with multiple comparisons) (Figure 4B, Supplemental Figure 4A). To evaluate the in vivo effect of these antibodies in a more stringent challenge model in 12-month old female BALB/c mice, we increased the viral dose from 1x10³ to 1x10⁴ PFU. In this experiment, mice that received antibody 46472-12 exhibited the best survival rate (4/5 at day 4), compared to the other treatment groups that included CR3022 as an antigen-specific control and DENV-2D22 as a negative control, although statistical significance
was not achieved (Figure 4C-D, Supplemental Figure 4B). There were no significant differences in viral load between groups; however, the surviving animals from the 46472-4 and 46472-12 groups showed significantly lower hemorrhagic pathology scores in harvested mouse lungs compared to the negative control treatment group (p<0.001, ordinary one-way ANOVA with multiple comparisons) (Figure 4C). Animals treated with the antigen-specific control, CR3022, had significantly higher hemorrhage scores than animals treated with 46472-4 and 46472-12 (p<0.001, ordinary one-way ANOVA with multiple comparisons), although the statistical analysis may be limited by the small numbers of surviving animals for some of the groups (Figure 4C). While definitive evidence for protection is limited, the data from the in vivo experiments suggests that these cross-reactive antibodies could contribute to counteracting coronavirus infection in prophylaxis.

DISCUSSION

Here, we described a set of cross-reactive Betacoronavirus antibodies isolated from a recovered SARS-CoV donor. The antibodies targeted diverse epitopes on S, including the S2 subdomain as well as the RBD and NTD on S1, and demonstrated Fc effector function in vitro. Additionally, two of these antibodies were tested in vivo, and displayed a reduction in lung hemorrhage score, while effects on viral load were not definitive. Given the similar effect of 46472-4 and 46472-12 on severe disease in the mouse model, their phagocytic ability along with the inability to mediate neutralization suggests that the former may be a mechanism through which they function, and additional studies are underway to further assess this hypothesis. Phagocytosis has been shown to be associated with protection in a SARS-CoV-2 DNA vaccination in non-human primates as well as survival in natural infection and as such could be an important mechanism for protection by monoclonal antibodies. The role of trogocytosis in COVID-19 is unknown as are the targets that may be
important for this function. 46472-4 was able to mediate this membrane nibbling in contrast to
46472-12, suggesting that this function in addition to complement activity was not responsible
for the in vivo effect on severe disease mediated by these antibodies. Although the precise in
vivo effects of these antibodies have not been elucidated, the identification of multiple, cross-
reactive antibodies highlights a potential role for Fc effector function activity, specifically
phagocytosis, in coronavirus infection. Evidence of protection associated with Fc effector
function in SARS-CoV\textsuperscript{22}, SARS-CoV-2\textsuperscript{23,24,34}, and other infectious diseases including influenza,
Ebola, and HIV, motivates further investigation into its contribution for the treatment of COVID-
19\textsuperscript{35–38}. Furthermore, the importance of Fc effector functionality of potently neutralizing
candidate clinical SARS-CoV-2 mAbs in a therapeutic setting rather than prophylaxis highlights
the potential benefit for investigation into non-neutralizing antibodies with phagocytic activity and
their administration after infection onset\textsuperscript{39}. Elucidation of the functional roles of cross-reactive
but non-neutralizing antibodies could have implications for understanding the factors involved in
protection or enhancement of disease.

Given the ongoing SARS-CoV-2 pandemic and the potential for future zoonotic coronavirus
pathogens to emerge, coronavirus vaccine and therapeutic development is of paramount
importance\textsuperscript{40–43}. Antibodies that can cross-react with multiple coronavirus strains are primary
targets as potential broadly reactive therapies. Such antibodies can further reveal cross-reactive
epitopes that could serve as templates for the development of broadly protective vaccines.
Understanding the spectrum of cross-reactive epitopes targeted by human antibodies, as well
as the functional role that such antibodies have within coronavirus infection, are therefore a vital
element of medical countermeasure development.

Limitations of the Study

The current study focuses on the characterization of cross-reactive coronavirus antibodies,
mostly in the context of SARS-CoV-2. Further characterization of this panel of antibodies
against circulating endemic coronavirus strains would enhance the clinical relevance to less severe coronavirus-associated respiratory infections.

The current study utilized a dosing regimen in a prophylactic setting and given the emerging evidence of survival benefit with effector function in antibodies given after infection onset\(^{39}\), antibody administration in a therapeutic setting may provide further insight into \textit{in vivo} properties. Furthermore, additional effector function characterization such as ADCC and ADNP would strengthen the profile of this panel of non-neutralizing antibodies given their role in both human\(^{44}\) and mouse SARS-CoV-2 infection studies.

**ACKNOWLEDGEMENTS**

We thank Angela Jones, Latha Raju, and Jamie Roberson of Vanderbilt Technologies for Advanced Genomics for their expertise regarding NGS and library preparation; David Flaherty and Brittany Matlock of the Vanderbilt Flow Cytometry Shared Resource for help with flow panel optimization; and members of the Georgiev laboratory for comments on the manuscript. The Vanderbilt VANTAGE Core provided technical assistance for this work. VANTAGE is supported in part by CTSA grant 5UL1 RR024975-03, the Vanderbilt Ingram Cancer Center (P30 CA68485), the Vanderbilt Vision Center (P30 EY08126), and NIH/NCRR (G20 RR030956). This work was conducted in part using the resources of the Advanced Computing Center for Research and Education at Vanderbilt University (Nashville, TN). Flow cytometry experiments were performed in the VUMC Flow Cytometry Shared Resource. The VUMC Flow Cytometry Shared Resource is supported by the Vanderbilt Ingram Cancer Center (P30 CA68485) and the Vanderbilt Digestive Disease Research Center (DK058404).

For work described in this manuscript, I.S.G., A.R.S., K.J.K., S.W., K.A.P., R.V., N.R., E.F.F., C.M.H. were supported in part by NIH NIAID award R01AI131722-S1, the Hays Foundation COVID-19 Research Fund, Fast Grants, and CTSA award No. UL1 TR002243 from the National
Center for Advancing Translational Sciences. J.S.M and D.W. were supported in part by a
National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)
grant awarded to J.S.M. (R01-AI127521). L.M. and S.I.R. acknowledge research funding from
the South African Medical Research Council (MRC) Extramural Unit and SHIP-COVID19
programs and an H3 Africa grant (U01A136677). S.I.R. is supported by the South African
Research Chairs Initiative of the Department of Science and Technology and the NRF (Grant
No 98341) and is a L’Oreal/UNESCO South Africa Young Talents Awardee. R.B., A.S., D.R.M.,
were supported by NIH grants (U54CA260543, R01AI157155). P.A. and K.J. were supported by
NIH grant R01 AI14567. J.E.C., R.H.C., N.S., R.N.S., and R.E.S., were supported by Defense
Advanced Research Projects Agency (DARPA) grants HR0011-18-2-0001 and HR00 11-18-3-
0001; NIH contracts 75N93019C00074 and 75N93019C00062; NIH grants U01 AI150739, R01
AI130591 and R35 HL145242; the Dolly Parton COVID-19 Research Fund at Vanderbilt; and
NIH grant S10 RR028106 for the Next Generation Nucleic Acid Sequencer, housed in
VANTAGE. M.S.D. and R.E.C. were supported by grants from NIH (R01 AI157155) and the
Defense Advanced Research Project Agency (HR001117S0019). B.F.H. and R.P. were
supported by NC State funding for COVID research. B.S.G. was supported by intramural
funding from the NIAID. C.M.H. was supported in part by NIH grant T32 GM008320-30. D.R.M.
was supported by an NIH F32 AI152296, a Burroughs Wellcome Fund Postdoctoral Enrichment
Program Award, and was previously supported by an NIH NIAID T32 AI007151.

AUTHOR CONTRIBUTIONS
Methodology, A.R.S., K.J.K., and I.S.G.; Investigation, A.R.S., K.J.K., D.W., S.I.R., A.S., S.W.,
N.W., K.J., K.A.P., R.V., R.P., N.P.M., N.R., E.F.F., C.M.H., N.S., R.E.C., D.R.M., R.S.N.,
R.E.S., J.E.L., B.S.G., M.S.D., B.F.H., P.A., R.H.C., J.E.C., R.S.B., L.M., J.S.M., and I.S.G.;
Software, A.R.S., R.V., N.R.; Validation, A.R.S., K.J.K.; Writing - Original Draft, A.R.S., and
K.J.K.; Writing -Review & Editing, all authors; Funding Acquisition, I.S.G., B.S.G., M.S.D.,
B.F.H., P.A., R.H.C., J.E.C., R.S.B., L.M., J.S.M., and A.R.S; Resources, B.S.G.,
M.S.D., B.F.H., P.A., R.H.C., J.E.C., R.S.B., L.M., J.S.M., and I.S.G; Supervision, I.S.G.

DECLARATION OF INTERESTS

A.R.S. and I.S.G are co-founders of AbSeek Bio. A.R.S., K.J.K, I.S.G., D.W., N.W., and J.S.M are listed as inventors on patents filed describing the antibodies described here. D.W., J.S.M, B.S.G, and N.W. are also listed as inventors on U.S. patent application no. 62/972,886 (2019-nCoV Vaccine). M.S.D. is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals, and Carnival Corporation and on the Scientific Advisory Boards of Moderna and Immunome. The Diamond laboratory has unrelated sponsored research agreements from Emergent BioSolutions, Moderna and Vir Biotechnology. J.E.C. has served as a consultant for Eli Lilly, GlaxoSmithKline and Luna Biologics, is a member of the Scientific Advisory Boards of CompuVax and Meissa Vaccines and is Founder of IDBiologics. The Crowe laboratory at Vanderbilt University Medical Center has received sponsored research agreements from IDBiologics and AstraZeneca. R.S.B. has competing interests associated with Eli Lily, Takeda and Pfizer. The Georgiev laboratory at Vanderbilt University Medical Center has received unrelated funding from Takeda Pharmaceuticals.

FIGURE CAPTIONS

Figure 1. Identification of coronavirus cross-reactive antibodies from SARS-CoV recovered PBMC sample using LIBRA-seq, see also Figure S1.

(A) Schematic of DNA-barcoded antigens used to probe a SARS-CoV donor PBMC sample.

(B) LIBRA-seq scores for SARS-CoV (x-axis) and SARS-CoV-2 (y-axis) for all IgG cells recovered from sequencing are shown as circles. 15 lead antibody candidates are highlighted in purple.

(C) Antibodies were tested for binding to CoV antigens by ELISA. HIV-specific antibody VRC01 was used as a negative control. Anti-SARS-CoV mouse antibody 240CD was also used.
ELISAs were performed in technical duplicates with at least two biological duplicates. Data are represented as mean ± SEM.

(D) ELISA binding data are displayed as a heatmap of the AUC values calculated from data in Figure 1C, with AUC of 0 as white, and maximum AUC as purple.

Figure 2. Epitope mapping of cross-reactive antibodies, see also Figure S2.

(A) For cross-reactive coronavirus antibodies, ELISA data against the antigens are displayed as a heatmap of the AUC values calculated from the data in Figure S2A. (B) For SARS-CoV-2 S1 reactive antibodies, ELISA data against the RBD and NTD are displayed as a heatmap of the AUC values calculated from the data in Figure S2B. AUC of 0 is displayed as white and maximum AUC as purple. ELISA data are representative of at least two independent experiments. Anti-HIV antibody VRC01 and anti-VEGF antibody are shown as a negative control, and anti-SARS-CoV antibody 240CD is shown as a positive control.

(C) Surface plasmon resonance binding of 46472-12 Fab to SARS-CoV-2 RBD. Affinity measurements are shown to the right of the graph.

(D) Cross-reactive antibodies were used in a competition ELISA to determine if binding of one antibody affected binding of another. Competitor antibodies were added at 10 µg/ml, and then detected antibodies were added at 0.1 µg/ml. The percent reduction in binding compared to binding without a competitor is shown. An anti-HIV antibody was used as a negative control. ELISAs were performed in technical duplicates with at least two biological duplicates.

(E) Antibodies were tested for autoreactivity against a variety of antigens in the Luminex Athena assay. AU stands for Athena Units. Anti-HIV antibody 4E10 was used as a positive control and Ab82 was used as a negative control.

(F) Cross-reactive coronavirus antibodies target a variety of epitopes on the SARS-CoV-2 S protein, including the RBD, NTD, and S2 domains, highlighted on the structure (PDB: 6VSB).

Figure 3. Functional activity of cross-reactive coronavirus antibodies, see also Figure S3.
Cross-reactive coronavirus antibodies were tested for antibody-dependent cellular
phagocytosis activity (ADCP) against SARS-CoV-2 S, compared to positive control CR3022 and
negative control Palivizumab, an anti-RSV antibody. AUC of the phagocytosis score is shown,
calculated from data in Figure S3C. Data are represented as mean ± SD.  

46472-4 and 46472-12 were tested for ADCP activity against SARS-CoV S, compared to
CR3022 and anti-RSV Palivizumab. AUC of the phagocytosis score is shown, calculated from
data in Figure S3D. Data are represented as mean ± SD.  

Cross-reactive coronavirus antibodies were tested for antibody-dependent cellular
trogocytosis (ADCT) activity against SARS-CoV-2 S displayed on transfected cells, compared to
positive control CR3022 and anti-RSV Palivizumab. AUC of the trogocytosis score is shown,
calculated from data in Figure S3E. Data are represented as mean ± SD.  

Cross-reactive coronavirus antibodies were tested for antibody-dependent complement
deposition (ADCD) activity against SARS-CoV-2 S, compared to positive control CR3022 and
anti-RSV Palivizumab. AUC of the C3b deposition score is shown, calculated from data in
Figure S3F. Data are represented as mean ± SD.  

**Figure 4.** *In vivo* effects of cross-reactive antibodies, see also Figure S4.  

(A) Timeline of the prophylactic antibody experiment in SARS-CoV-2 mouse adapted (MA) *in
vivo* infection model.  

(B,C) For each antibody treatment group for the experiment utilizing (B) 1x10^3 PFU or (C) 1x10^4
PFU of SARS-CoV-2 MA, shown are daily body weight progression, and terminal RT-qPCR
quantification of lung viral titer and lung hemorrhage scores of gross pathology. For viral titer
values and the lung hemorrhage scores, an ordinary one-way ANOVA test with multiple
comparisons was performed.  

(D) For the experiment with 1x10^4 PFU of SARS-CoV-2 MA, percent survival for each antibody
group is shown.
STAR Methods

RESOURCE AVAILABILITY

Lead Contact

Further information and requests for resources and reagents should be directed to the Lead Contact, Ivelin Georgiev (Ivelin.Georgiev@Vanderbilt.edu).

Materials Availability

All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement. Please direct resource and reagent requests to the Lead Contact specified above, Ivelin Georgiev.

Data and Code Availability

Sequences for antibodies identified and characterized in this study have been deposited to GenBank under GenBank accession numbers MZ126644-MZ126658 (heavy chain) and MZ126659-MZ126673 (light chain). Raw sequencing data used in this study are available on the Sequence Read Archive under BioProject accession number PRJNA727275. Custom scripts used to analyze data in this manuscript are available upon request to the corresponding author.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human subjects

The donor had prior SARS-CoV infection during the 2004 outbreak in Hong Kong, and the PBMC sample was collected over 10 years post infection (20 million PBMCs). Additional information about the donor is not available.

Cell lines

A variety of cell lines were utilized for various assays in this study.
Expi293F mammalian cells (ThermoFisher) were maintained in FreeStyle F17 expression medium supplemented at final concentrations of 0.1% Pluronic Acid F-68 and 20% 4mM L-Glutamine. These cells were cultured at 37°C with 8% CO₂ saturation and shaking. FreeStyle293F cells were grown while shaking at 37°C in 8% CO₂ and 80% humidity. Freestyle293F cells are derived from female human embryonic kidney epithelial cells.

THP-1 cells obtained from the AIDS Reagent Program (Division of AIDS, NIAID, NIH) contributed by Dr. Li Wu and Vineet N. KewalRamani were used for both the ADCP and ADCT assays. Cells were cultured at 37°C, 5% CO₂ in RPMI containing 10% heat-inactivated fetal bovine serum (Gibco, Gaithersburg, MD), 1% Penicillin Streptomycin (Gibco, Gaithersburg, MD) and 2-mercaptoethanol to a final concentration of 0.05 mM. These cells were not allowed to exceed 4 x 10⁵ cells/ml to prevent differentiation and are from a male donor.

HEK293T cells were obtained from Dr George Shaw and were used for the ADCT assay. These adherent cell lines were cultured at 37°C, 5% CO₂, in DMEM containing 10% heat-inactivated fetal bovine serum (Gibco BRL Life Technologies) and supplemented with 50 µg/ml gentamicin (Sigma). Cells were disrupted at confluence with 0.25% trypsin in 1 mM EDTA (Sigma) every 48–72 hours. HEK293F suspension cells were cultured in 293Freestyle media (Gibco BRL Life Technologies) and grown in a shaking incubator at 37°C, 5% CO₂, 70% humidity at 125rpm. Cells were diluted twice a week to between 0.2 and 0.5 million cells/ml. Both HEK293 derived cell lines are from female donors.

Murine Model

12-month old female BALB/c mice (BALB/cAnHsd; Envigo, stock number 047) were used in a murine infection model for SARS-CoV-2 with a mouse adapted strain. Eleven to twelve-month old female BALB/c mice (BALB/c AnNHsd, Envigo, stock# 047) were used for mouse-adapted SARS-CoV-2 (SARS-CoV-2 MA10) in vivo protection experiments as described previously. All mouse studies were performed at the University of North Carolina.
(Animal Welfare Assurance #A3410-01) using protocols (19-168) approved by the UNC Institutional Animal Care and Use Committee (IACUC) and were performed in a BSL3 facility at UNC.

METHOD DETAILS

Antigen Purification

A variety of recombinant soluble protein antigens were used in the LIBRA-seq experiment and other experimental assays.

Plasmids encoding residues 1–1208 of the SARS-CoV-2 spike with a mutated S1/S2 cleavage site, proline substitutions at positions 986 and 987, and a C-terminal T4-fibritin trimerization motif, an 8x HisTag, and a TwinStrepTag (SARS-CoV-2 S-2P); residues 1-1190 of the SARS-CoV spike with proline substitutions at positions 968 and 969, and a C-terminal T4-fibritin trimerization motif, an 8x HisTag, and a TwinStrepTag (SARS-CoV S-2P); residues 1-1291 of the MERS-CoV spike with proline substitutions at positions 968 and 969, and a C-terminal T4-fibritin trimerization motif, an 8x HisTag, and a TwinStrepTag (MERS-CoV S-2P Avi); residues 1-1291 of the MERS-CoV spike with proline substitutions at positions 1060 and 1061, and a C-terminal T4-fibritin trimerization motif, an AviTag, an 8x HisTag, and a TwinStrepTag (MERS-CoV S1); residues 1-1277 of the HCoV-HKU1 spike with a mutated S1/S2 cleavage site, proline substitutions at positions 1067 and 1068, and a C-terminal T4-fibritin trimerization motif, an 8x HisTag, and a TwinStrepTag (MERS-CoV S1); residues 1-751 of the MERS-CoV spike with a C-terminal T4-fibritin trimerization motif, 8x HisTag, and a TwinStrepTag (MERS-CoV S1); residues 1-1278 of the HCoV-OC43 spike with proline substitutions at positions 1070 and 1071, and a C-terminal T4-fibritin trimerization motif, an 8x HisTag, and a TwinStrepTag (HCoV-OC43 S-2P); or residues 319–591 of SARS-CoV-2 S with a C-terminal monomeric human IgG Fc-tag and an 8x HisTag (SARS-CoV-2 RBD-SD1) were transiently transfected into FreeStyle293F cells (Thermo Fisher) using polyethylenimine. The coronavirus trimer spike antigens were in a prefusion-stabilized (S-2P) conformation that better
represents neutralization-sensitive epitopes in comparison to their wild-type forms. Two hours post-transfection, cells were treated with kifunensine to ensure uniform glycosylation. Transfected supernatants were harvested after 6 days of expression. SARS-CoV-2 RBD-SD1 was purified using Protein A resin (Pierce), SARS-CoV-2 S-2P, SARS-CoV S-2P, MERS-CoV S-2P Avi, MERS-CoV S1, HCoV-HKU1 S-2P and HCoV-OC43 S-2P were purified using StrepTactin resin (IBA). Affinity-purified SARS-CoV-2 RBD-SD1 was further purified over a Superdex75 column (GE Life Sciences). MERS-CoV S1 was purified over a Superdex200 Increase column (GE Life Sciences). SARS-CoV-2 S-2P, SARS-CoV S-2P, MERS-CoV S-2P Avi, HCoV-HKU1 S-2P and HCoV-OC43 S-2P were purified over a Superose6 Increase column (GE Life Sciences).

For the HIV-1 gp140 SOSIP variant from strain ZM197 (clade C) and CZA97 (clade C), recombinant, soluble antigens contained an AviTag and were expressed in Expi293F cells using polyethylenimine transfection reagent and cultured. FreeStyle F17 expression medium supplemented with pluronic acid and glutamine was used. The cells were cultured at 37°C with 8% CO₂ saturation and shaking. After 5-7 days, cultures were centrifuged and supernatant was filtered and run over an affinity column of agarose bound *Galanthus nivalis* lectin. The column was washed with PBS and antigens were eluted with 30 mL of 1M methyl-a-D-mannopyranoside. Protein elutions were buffer exchanged into PBS, concentrated, and run on a Superdex 200 Increase 10/300 GL Sizing column on the AKTA FPLC system. Fractions corresponding to correctly folded protein were collected, analyzed by SDS-PAGE and antigenicity was characterized by ELISA using known monoclonal antibodies specific to each antigen. Avi-tagged antigens were biotinylated using BirA biotin ligase (Avidity LLC). Non-Avi-tagged antigens were biotinylated using the EZ-Link Sulfo-NHS-Biotin kits using a 50:1 biotin to protein molar ratio.
For binding studies, SARS-CoV-2 HexaPro S, SARS-CoV S, SARS-CoV-2 RBD, SARS-CoV RBD, and MERS-CoV RBD constructs were expressed in the transient expression system previously mentioned. S proteins were purified using StrepTrap HP columns and RBD constructs were purified over protein A resin, respectively. Each resulting protein was further purified to homogeneity by size-exclusion chromatography on a Superose 6 10/300 GL column.

SARS-CoV-2 S1, SARS-CoV-2 S1 D614G, SARS-CoV-2 S2, and SARS-CoV-2 NTD truncated proteins were purchased from the commercial vendor, Sino Biological.

**DNA-barcoding of Antigens**

We used oligos that possess 15 bp antigen barcode, a sequence capable of annealing to the template switch oligo that is part of the 10X bead-delivered oligos, and contain truncated TruSeq small RNA read 1 sequences in the following structure: 5'-

CCTTGCCACCCGAGAATTCCANNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
the 4FB-oligo and the HyNic-antigen were mixed together. This causes a stable bond to form between the protein and the oligonucleotide. The concentration of the antigen-oligo conjugates was determined by a BCA assay, and the HyNic molar substitution ratio of the antigen-oligo conjugates was analyzed using the NanoDrop according to the Solulink protocol guidelines. AKTA FPLC was used to remove excess oligonucleotide from the protein-oligo conjugates, which were also verified using SDS-PAGE with a silver stain. Antigen-oligo conjugates were also used in flow cytometry titration experiments.

Antigen specific B cell sorting

Cells were stained and mixed with DNA-barcodecd antigens and other antibodies, and then sorted using fluorescence activated cell sorting (FACS). First, cells were counted and viability was assessed using Trypan Blue. Then, cells were washed three times with DPBS supplemented with 0.1% Bovine serum albumin (BSA). Cells were resuspended in DPBS-BSA and stained with cell markers including viability dye (Ghost Red 780), CD14-APC-Cy7, CD3-FITC, CD19-BV711, and IgG-PE-Cy5. Additionally, antigen-oligo conjugates were added to the stain. After staining in the dark for 30 minutes at room temperature, cells were washed three times with DPBS-BSA at 300 g for five minutes. Cells were then incubated for 15 minutes at room temperature with Streptavidin-PE to label cells with bound antigen. Cells were washed three times with DPBS-BSA, resuspended in DPBS, and sorted by FACS. Antigen positive cells were bulk sorted and delivered to the Vanderbilt Technologies for Advanced Genomics (VANTAGE) sequencing core at an appropriate target concentration for 10X Genomics library preparation and subsequent sequencing. FACS data were analyzed using FlowJo.

Sample and Library Preparation, and Sequencing

Single-cell suspensions were loaded onto the Chromium Controller microfluidics device (10X Genomics) and processed using the B-cell Single Cell V(D)J solution according to
manufacturer’s suggestions for a target capture of 10,000 B cells per 1/8 10X cassette, with minor modifications in order to intercept, amplify and purify the antigen barcode libraries as previously described.

**Sequence Processing and Bioinformatic Analysis**

We utilized and modified our previously described pipeline to use paired-end FASTQ files of oligo libraries as input, process and annotate reads for cell barcode, UMI, and antigen barcode, and generate a cell barcode - antigen barcode UMI count matrix. BCR contigs were processed using Cell Ranger (10X Genomics) using GRCh38 as reference. Antigen barcode libraries were also processed using Cell Ranger (10X Genomics). The overlapping cell barcodes between the two libraries were used as the basis of the subsequent analysis. We removed cell barcodes that had only non-functional heavy chain sequences as well as cells with multiple functional heavy chain sequences and/or multiple functional light chain sequences, reasoning that these may be multiplets. Additionally, we aligned the BCR contigs (filtered_contigs.fasta file output by Cell Ranger, 10X Genomics) to IMGT reference genes using HighV-Quest. The output of HighV-Quest was parsed using ChangeO and merged with an antigen barcode UMI count matrix. Finally, we determined the LIBRA-seq score for each antigen in the library for every cell as previously described.

**Antibody Expression and Purification**

For each antibody, variable genes were inserted into custom plasmids encoding the constant region for the IgG1 heavy chain as well as respective lambda and kappa light chains (pTwist CMV BetaGlobin WPRE Neo vector, Twist Bioscience). Antibodies were expressed in Expi293F mammalian cells (ThermoFisher) by co-transfecting heavy chain and light chain expressing plasmids using polyethyleneimine transfection reagent and cultured for 5-7 days. Cells were maintained in FreeStyle F17 expression medium supplemented at final concentrations of 0.1%
Pluronic Acid F-68 and 20% 4mM L-Glutamine. These cells were cultured at 37°C with 8% CO₂ saturation and shaking. After transfection and 5-7 days of culture, cell cultures were centrifuged and supernatant was 0.45 µm filtered with Nalgene Rapid Flow Disposable Filter Units with PES membrane. Filtered supernatant was run over a column containing Protein A agarose resin equilibrated with PBS. The column was washed with PBS, and then antibodies were eluted with 100 mM Glycine HCl at 2.7 pH directly into a 1:10 volume of 1M Tris-HCl pH 8.0. Eluted antibodies were buffer exchanged into PBS 3 times using Amicon Ultra centrifugal filter units and concentrated. Antibodies were analyzed by SDS-PAGE. Additionally, antibodies 46472-1, 46472-2, 46472-3, 46472-4, 46472-6 and 46472-12 were assessed by size exclusion chromatography on a Superdex 200 Increase 10/300 GL Sizing column with the AKTA FPLC system.

**High-throughput Antibody Expression**

For high-throughput production of recombinant antibodies, approaches were used that are designated as microscale. For antibody expression, microscale transfection were performed (~1 ml per antibody) of CHO cell cultures using the Gibco ExpiCHO Expression System and a protocol for deep 96-well blocks (Thermo Fisher Scientific). In brief, synthesized antibody-encoding DNA (~2 µg per transfection) was added to OptiPro serum free medium (OptiPro SFM), incubated with ExpiFectamine CHO Reagent and added to 800 µl of ExpiCHO cell cultures into 96-deep-well blocks using a ViaFlo 384 liquid handler (Integra Biosciences). The plates were incubated on an orbital shaker at 1,000 r.p.m. with an orbital diameter of 3 mm at 37°C in 8% CO₂. The next day after transfection, ExpiFectamine CHO Enhancer and ExpiCHO Feed reagents (Thermo Fisher Scientific) were added to the cells, followed by 4 d incubation for a total of 5 d at 37°C in 8% CO₂. Culture supernatants were collected after centrifuging the blocks at 450g for 5 min and were stored at 4°C until use. For high-throughput microscale antibody purification, fritted deep-well plates were used containing 25 µl of settled protein G.
resin (GE Healthcare Life Sciences) per well. Clarified culture supernatants were incubated with protein G resin for mAb capturing, washed with PBS using a 96-well plate manifold base (Qiagen) connected to the vacuum and eluted into 96-well PCR plates using 86 µl of 0.1 M glycine-HCL buffer pH 2.7. After neutralization with 14 µl of 1 M Tris-HCl pH 8.0, purified mAbs were buffer-exchanged into PBS using Zeba Spin Desalting Plates (Thermo Fisher Scientific) and stored at 4°C until use.

ELISA

To assess antibody binding, soluble protein was plated at 2 µg/ml overnight at 4°C. The next day, plates were washed three times with PBS supplemented with 0.05% Tween-20 (PBS-T) and coated with 5% milk powder in PBS-T. Plates were incubated for one hour at room temperature and then washed three times with PBS-T. Primary antibodies were diluted in 1% milk in PBS-T, starting at 10 µg/ml with a serial 1:5 dilution and then added to the plate. The plates were incubated at room temperature for one hour and then washed three times in PBS-T. The secondary antibody, goat anti-human IgG conjugated to peroxidase, was added at 1:10,000 dilution in 1% milk in PBS-T to the plates, which were incubated for one hour at room temperature. Goat anti-mouse secondary was used for SARS-CoV specific control antibody 240CD (BEI Resources). Plates were washed three times with PBS-T and then developed by adding TMB substrate to each well. The plates were incubated at room temperature for ten minutes, and then 1N sulfuric acid was added to stop the reaction. Plates were read at 450 nm.

Data are represented as mean ± SEM for one ELISA experiment. ELISAs were repeated 2 or more times. The area under the curve (AUC) was calculated using GraphPad Prism 8.0.0. For antibody 240CD, the following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-SARS-CoV S Protein (Similar to 240C), NR-616.

Competition ELISA
Competition ELISAs were performed as described above, with some modifications. After coating with antigen and blocking, 25 µl of non-biotinylated competitor antibody was added to each well at 10 µg/ml and incubated at 37°C for 10 minutes. Then, without washing, 75 µl biotinylated antibody (final concentration of 1 µg/ml) was added and incubated at 37°C for 1 hour. After washing three times with PBS-T, streptavidin-HRP was added at 1:10,000 dilution in 1% milk in PBS-T and incubated for 1 hour at room temperature. Plates were washed and substrate and sulfuric acid were added as described above. ELISAs were repeated at least 2 times. Data is shown as the % decrease in binding.

**Autoreactivity**

Monoclonal antibody reactivity to nine autoantigens (SSA/Ro, SS-B/La, Sm, ribonucleoprotein (RNP), Scl 70, Jo-1, dsDNA, centromere B, and histone) was measured using the AtheNA Multi-Lyte® ANA-II Plus test kit (Zeus scientific, Inc, #A21101). Antibodies were incubated with AtheNA beads for 30min at concentrations of 50, 25, 12.5 and 6.25 µg/mL. Beads were washed, incubated with secondary and read on the Luminex platform as specified in the kit protocol. Data were analyzed using AtheNA software. Positive (+) specimens received a score >120, and negative (-) specimens received a score <100. Samples between 100-120 were considered indeterminate.

**Mannose competition**

Mannose competition ELISAs were performed as described above with minor modifications. After antigen coating and washing, nonspecific binding was blocked by incubation with 5% FBS diluted in PBS for 1 hour at RT. Primary antibodies were diluted in 5% FBS-PBST +/- 1M D-(+)-Mannose starting at 10 µg/ml with a serial 1:5 dilution and then added to the plate for 1 hour at RT. After washing, antibody binding was detected with goat anti-human IgG conjugated to peroxidase and added at 1:10,000 dilution in 5% FBS in PBS-T to the plates. After 1 hour
incubation, plates were washed and substrate and sulfuric acid were added as described above.

Data shown is representative of three replicates.

Epitope Mapping Visualization

SARS-CoV-2 Spike (PDB-6VSB) was visualized using PyMOL software. Antibody epitopes were visualized on the SARS-CoV-2 spike using a structure of the pre-fusion stabilized SARS-CoV-2 S-2P construct\(^5\) modeled in the molecular graphics software PyMOL (The PyMOL Molecular Graphics System, Version 2.3.5 Schrödinger, LLC).

RTCA Neutralization Assay

To assess for neutralizing activity against SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 (obtained from the Centers for Disease Control and Prevention, a gift from N. Thornburg), we used the high-throughput RTCA assay and xCelligence RTCA HT Analyzer (ACEA Biosciences) that has been described previously\(^1\). After obtaining a background reading of a 384-well E-plate, 6,000 Vero-furin cells\(^4\) were seeded per well. Sensograms were visualized using RTCA HT software version 1.0.1 (ACEA Biosciences). One day later, equal volumes of virus were added to antibody samples and incubated for 1 h at 37°C in 5% CO\(_2\). mAbs were tested in triplicate with a single (1:20) dilution. Virus–mAb mixtures were then added to Vero-furin cells in 384-well E-plates. Controls were included that had Vero-furin cells with virus only (no mAb) and media only (no virus or mAb). E-plates were read every 8–12 h for 72 h to monitor virus neutralization. At 32 h after virus-mAb mixtures were added to the E-plates, cell index values of antibody samples were compared to those of virus only and media only to determine presence of neutralization.

Nano-luciferase Neutralization Assay
A full-length SARS-CoV-2 virus based on the Seattle Washington isolate and a full-length SARS-CoV virus based on the Urbani isolate were designed to express luciferase and was recovered via reverse genetics and described previously. Viruses were titered in Vero E6 USAMRID cells to obtain a relative light units (RLU) signal of at least 10X the cell only control background. Vero E6 USAMRID cells were plated at 20,000 cells per well the day prior in clear bottom black walled 96-well plates (Corning 3904). Neutralizing antibody serum samples were tested at a starting dilution of 1:40 and were serially diluted 4-fold up to eight dilution spots. Antibody-virus complexes were incubated at 37°C with 5% CO2 for 1 hour. Following incubation, growth media was removed and virus-antibody dilution complexes were added to the cells in duplicate. Virus-only controls and cell-only controls were included in each neutralization assay plate. Following infection, plates were incubated at 37°C with 5% CO2 for 48 hours. After the 48 hour incubation, cells were lysed and luciferase activity was measured via Nano-Glo Luciferase Assay System (Promega) according to the manufacturer specifications. SARS-CoV and SARS-CoV-2 neutralization titers were defined as the sample dilution at which a 50% reduction in RLU was observed relative to the average of the virus control wells.

**SPR**

His-tagged SARS-CoV-2 RBD-SD1 was immobilized to a NiNTA sensorchip to a level of ~150 RU using a Biacore X100. Serial dilutions of purified Fab 46472-12 were evaluated for binding, ranging in concentration from 1 to 0.25 µM. The resulting data were fit to a 1:1 binding model using Biacore Evaluation Software.

**Fc Effector function Assays**

**Antibody-dependent Cellular Phagocytosis (ADCP)**

Antibody-dependent cellular phagocytosis (ADCP) was performed using biotinylated SARS-CoV-2 or SARS-CoV S coated fluorescent neutravidin beads as previously described. Briefly,
beads were incubated for two hours with antibodies at a starting concentration of 50µg/ml and titrated five fold. CR3022 was used as a positive control while Palivizumab was used as a negative control. Antibodies and beads were incubated with THP-1 cells overnight, fixed and interrogated on the FACS Aria II. Phagocytosis score was calculated as the percentage of THP-1 cells that engulfed fluorescent beads multiplied by the geometric mean fluorescence intensity of the population in the FITC channel less the no antibody control.

Antibody-dependent Cellular Trogocytosis (ADCT)

ADCT was performed as described in and modified from a previously described study\textsuperscript{29}. HEK293T cells transfected with a SARS-CoV-2 spike pcDNA vector were surface biotinylated with EZ-Link Sulfo-NHS-LC-Biotin as recommended by the manufacturer. Fifty-thousand cells per well were incubated with antibody for 30 minutes starting at 25µg/ml and titrated 5 fold. CR3022 was used as a positive control with Palivizumab as a negative. Following a RPMI media wash, these were then incubated with carboxyfluorescein succinimidyl ester (CFSE) stained THP-1 cells (5 X10\textsuperscript{4} cells per well) for 1 hour and washed with 15mM EDTA/PBS followed by PBS. Cells were then stained for biotin using Streptavidin-PE and read on a FACS Aria II. Trogocytosis score was determined as the proportion of CFSE positive THP-1 cells also positive for streptavidin-PE less the no antibody control.

Antibody-dependent Complement Deposition (ADCD)

Antibody-dependent complement deposition was performed as previously described\textsuperscript{52}. Briefly, biotinylated SARS-Cov-2 S protein was coated 1:1 onto fluorescent neutravidin beads for 2 hours at 37 degrees. These beads were incubated with 100µg/ml of antibody for 1 hour and incubated with guinea pig complement diluted 1 in 50 with gelatin/veronal buffer for 15 minutes at 37 degrees. Beads were washed at 2000g twice in PBS and stained with anti-guinea pig C3b-FITC, fixed and interrogated on a FACS Aria II. Complement deposition score was calculated as
the percentage of C3b-FITC positive beads multiplied by the geometric mean fluorescent
intensity of FITC in this population less the no antibody or heat inactivated controls.

**Antibody Prophylaxis - Murine Model of Infection**

For evaluating the prophylactic efficacy of mAbs, 12-month old female BALB/c mice
(BALB/cAnHsd; Envigo, stock number 047) were treated with 200 µg mAb intraperitoneally (i.p.)
12 hours prior to virus inoculation. The next day, mice were administered intranasally with 1x10^3
PFU or 1x10^4 PFU of SARS-CoV-2 MA10, respectively. Mice were monitored daily for weight
loss, morbidity, and mortality, and after four days, mice were sacrificed and lung tissue was
harvested for viral titer as measured by plaque assays. One lung lobe was taken for
pathological analysis and the other lobe was processed for qPCR and viral load determination
as previously described. For viral plaque assays, the caudal lobe of the right lung was
homogenized in PBS, and the tissue homogenate was then serial-diluted onto confluent
monolayers of Vero E6 cells, followed by agarose overlay. Plaques were visualized with overlay
of Neutral Red dye on day 2 post infection. Gross pulmonary hemorrhage was observed at time
of tissue harvest and scored on a scale of 0 (no hemorrhage in any lobe, normal pink healthy
lung) to 4 (complete hemorrhage in all lobes of the lung, completely dark red lung).

For viral titer and hemorrhage score comparisons, an ordinary one-way ANOVA test with
multiple comparisons was performed using Prism software, GraphPad Prism version 8.0.

**ACE2 Binding Inhibition Assay**

Wells of 384-well microtiter plates were coated with purified recombinant SARS-CoV-2 S-2P
ectoprotein at 4°C overnight. Plates were blocked with 2% non-fat dry milk and 2% normal goat
serum in DPBS-T for 1 hr. Purified mAbs were diluted two-fold in blocking buffer starting from 10
µg/mL in triplicate, added to the wells (20 µL/well), and incubated at ambient temperature.
Recombinant human ACE2 with a C-terminal FLAG tag protein was added to wells at 2 \( \mu \)g/mL in a 5 \( \mu \)L/well volume (final 0.4 \( \mu \)g/mL concentration of ACE2) without washing of antibody and then incubated for 40 min at ambient temperature. Plates were washed, and bound ACE2 was detected using HRP-conjugated anti-FLAG antibody and TMB substrate. ACE2 binding without antibody served as a control. Experiment was done in biological replicate and technical triplicates, shown is representative of one replicate with positive control mAb COV2-2196\(^{11}\).

**Identification of Residue-level Mutants**

Potential cross-reactive epitopes were identified based on sequence and structural homology. Reference sequences for each Coronavirus S were obtained either from NCBI for SARS-CoV-2 (YP_009724390.1) and MERS-CoV (YP_009047204.1) or from Uniprot for SARS-CoV (P59594) of the spikes was then obtained using MUSCLE\(^{53}\) and the amino acid similarity to SARS-CoV-2 at each residue position was calculated using the BLOSUM-62 scoring matrix\(^{54}\). These scores were then used to color each residue position on the SARS-CoV-2 S structure (PDB ID: 6VSB) in PyMOL (Schrodinger, version 2.3.5) in order to visualize surface patches and linear epitopes with structural homology. These conserved regions were then visualized on the other human coronavirus spike structures by retrieving them from the Protein Databank (SARS-CoV: 5X5B, MERS-CoV: 5W9I) and aligning them to the SARS-CoV-2 S structure. Finally, the residue N165 was part of a conserved surface patches and was mutated to alanine and tested for binding with antibodies. The N709A mutant tested was previously described in Acharya et al., BioRxiv (2020).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

ELISA error bars (standard error of the mean) were calculated using GraphPad Prism version 8.0.0. ANOVA analysis (ordinary one way ANOVA with multiple comparisons) was performed on
viral load titers and hemorrhage scores from animal experiments using GraphPad Prism version 8.0.0. Details of the statistical analyses can be found in the main text and figure captions.
REFERENCES

1. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 395, 565–574.

2. Graham, R.L., and Baric, R.S. (2010). Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission. JVI 84, 3134–3146.

3. Bosch, B.J., van der Zee, R., de Haan, C.A.M., and Rottier, P.J.M. (2003). The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex. JVI 77, 8801–8811.

4. Tortorici, M.A., and Veesler, D. (2019). Structural insights into coronavirus entry. In Advances in Virus Research, (Elsevier), pp. 93–116.

5. Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.-L., Abiona, O., Graham, B.S., and McLellan, J.S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263.

6. Jiang, S., Hillyer, C., and Du, L. (2020). Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends in Immunology 41, 355–359.

7. Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature 586, 516–527.

8. Li, F. (2016). Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu. Rev. Virol. 3, 237–261.

9. Brouwer, P.J.M., Caniels, T.G., van der Straten, K., Snitselaar, J.L., Aldon, Y., Bangaru, S., Torres, J.L., Okba, N.M.A., Claireaux, M., Kerster, G., et al. (2020). Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643–650.

10. Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020). A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650–655.
11. Zost, S.J., Gilchuk, P., Chen, R.E., Case, J.B., Reidy, J.X., Trivette, A., Nargi, R.S., Sutton, R.E., Suryadevara, N., Chen, E.C., et al. (2020). Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med 26, 1422–1427.

12. Pinto, D., Park, Y.-J., Beltramello, M., Walls, A.C., Tortorici, M.A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020). Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295.

13. Rogers, T.F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020). Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956–963.

14. Chen, P., Nirula, A., Heller, B., Gottlieb, R.L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021). SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med 384, 229–237.

15. Cohen, M.S. (2021). Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection. N Engl J Med 384, 289–291.

16. Weinreich, D.M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B.J., Soo, Y., Rofail, D., Im, J., et al. (2021). REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med 384, 238–251.

17. Liu, H., Wu, N.C., Yuan, M., Bangaru, S., Torres, J.L., Caniels, T.G., van Schooten, J., Zhu, X., Lee, C.-C.D., Brouwer, P.J.M., et al. (2020). Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity S1074761320304647.

18. Wec, A.Z., Wrapp, D., Herbert, A.S., Maurer, D.P., Haslwanter, D., Sakharkar, M., Jangra, R.K., Dieterle, M.E., Lilov, A., Huang, D., et al. (2020). Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731–736.
19. Lv, H., Wu, N.C., Tsang, O.T.-Y., Yuan, M., Perera, R.A.P.M., Leung, W.S., So, R.T.Y., Chan, J.M.C., Yip, G.K., Chik, T.S.H., et al. (2020). Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Reports 31, 107725.

20. Zohar, T., and Alter, G. (2020). Dissecting antibody-mediated protection against SARS-CoV-2. Nat Rev Immunol 20, 392–394.

21. Ng, K.W., Faulkner, N., Cornish, G.H., Rosa, A., Harvey, R., Hussain, S., Ulferts, R., Earl, C., Wrobel, A.G., Benton, D.J., et al. (2020). Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370, 1339–1343.

22. Yasui, F., Kohara, M., Kitabatake, M., Nishiwaki, T., Fuji, H., Tateno, C., Yoneda, M., Morita, K., Matsushima, K., Koyasu, S., et al. (2014). Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus. Virology 454–455, 157–168.

23. Schäfer, A., Muecksch, F., Lorenzi, J.C.C., Leist, S.R., Cipolla, M., Bournazos, S., Schmidt, F., Maison, R.M., Gazumyan, A., Martinez, D.R., et al. (2021). Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. Journal of Experimental Medicine 218, e20201993.

24. Atyeo, C., Fischinger, S., Zohar, T., Slein, M.D., Burke, J., Loos, C., McCulloch, D.J., Newman, K.L., Wolf, C., Yu, J., et al. (2020). Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. Immunity 53, 524-532.

25. Loos, C., Atyeo, C., Fischinger, S., Burke, J., Slein, M.D., Streeck, H., Lauffenburger, D., Ryan, E.T., Charles, R.C., and Alter, G. (2020). Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity. MSphere 5, e00622-20.

26. Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11, 1620.
27. Setliff, I., Shiakolas, A.R., Pilewski, K.A., Murji, A.A., Mapengo, R.E., Janowska, K., Richardson, S., Oosthuysen, C., Raju, N., Ronsard, L., et al. (2019). High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell 179, 1636-1646.

28. Yuan, M., Wu, N.C., Zhu, X., Lee, C.-C.D., So, R.T.Y., Lv, H., Mok, C.K.P., and Wilson, I.A. (2020). A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630–633.

29. Richardson, S.I., Crowther, C., Mkhize, N.N., and Morris, L. (2018). Measuring the ability of HIV-specific antibodies to mediate trogocytosis. Journal of Immunological Methods 463, 71–83.

30. Dinnon, K.H., Leist, S.R., Schäfer, A., Edwards, C.E., Martinez, D.R., Montgomery, S.A., West, A., Yount, B.L., Hou, Y.J., Adams, L.E., et al. (2020). A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560–566.

31. Leist, S.R., Dinnon, K.H., Schäfer, A., Tse, L.V., Okuda, K., Hou, Y.J., West, A., Edwards, C.E., Sanders, W., Fritch, E.J., et al. (2020). A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell 183, 1070-1085.

32. Yu, J., Tostanoski, L.H., Peter, L., Mercado, N.B., McMahan, K., Mahrokhian, S.H., Nkolola, J.P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020). DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806–811.

33. Zohar, T., and Alter, G. (2020). Dissecting antibody-mediated protection against SARS-CoV-2. Nat Rev Immunol 20, 392–394.

34. Atyeo, C., Slein, M.D., Fischinger, S., Burke, J., Schäfer, A., Leist, S.R., Kuzmina, N.A., Mire, C., Honko, A., Johnson, R., et al. (2021). Dissecting strategies to tune the therapeutic potential of SARS-CoV-2–specific monoclonal antibody CR3022. JCI Insight 6, e143129.
35. Bournazos, S., Klein, F., Pietzsch, J., Seaman, M.S., Nussenzweig, M.C., and Ravetch, J.V. (2014). Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity. Cell 158, 1243–1253.

36. Bournazos, S., DiLillo, D.J., Goff, A.J., Glass, P.J., and Ravetch, J.V. (2019). Differential requirements for FcγR engagement by protective antibodies against Ebola virus. Proc Natl Acad Sci USA 116, 20054–20062.

37. DiLillo, D.J., Palese, P., Wilson, P.C., and Ravetch, J.V. (2016). Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. Journal of Clinical Investigation 126, 605–610.

38. Lu, L.L., Suscovich, T.J., Fortune, S.M., and Alter, G. (2018). Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol 18, 46–61.

39. Winkler, E.S., Gilchuk, P., Yu, J., Bailey, A.L., Chen, R.E., Chong, Z., Zost, S.J., Jang, H., Huang, Y., Allen, J.D., et al. (2021). Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell 184, 1804–1820.e16.

40. Edwards, C.E., Yount, B.L., Graham, R.L., Leist, S.R., Hou, Y.J., Dinnon, K.H., Sims, A.C., Swanstrom, J., Gully, K., Scobey, T.D., et al. (2020). Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. Proc Natl Acad Sci U S A 117, 26915–26925.

41. Menachery, V.D., Yount, B.L., Sims, A.C., Debbink, K., Agnihotram, S.S., Gralinski, L.E., Graham, R.L., Scobey, T., Plante, J.A., Royal, S.R., et al. (2016). SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci USA 113, 3048–3053.

42. Menachery, V.D., Yount, B.L., Debbink, K., Agnihothram, S., Gralinski, L.E., Plante, J.A., Graham, R.L., Scobey, T., Ge, X.-Y., Donaldson, E.F., et al. (2015). A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med 21, 1508–1513.
43. Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., and Qin, C. (2019). From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses 11, 59.

44. Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M.D., Burke, J., Yu, J., Feldman, J., Hauser, B.M., et al. (2020). Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. Cell 183, 1508-1519.e12.

45. Pallesen, J., Wang, N., Corbett, K.S., Wrapp, D., Kirchdoerfer, R.N., Turner, H.L., Cottrell, C.A., Becker, M.M., Wang, L., Shi, W., et al. (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA 114, E7348–E7357.

46. Alamyar, E., Duroux, P., Lefranc, M.-P., and Giudicelli, V. (2012). IMGT® Tools for the Nucleotide Analysis of Immunoglobulin (IG) and T Cell Receptor (TR) V-(D)-J Repertoires, Polymorphisms, and IG Mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. Methods Mol Biol. 882, 569-604.

47. Gupta, N.T., Vander Heiden, J.A., Uduman, M., Gadala-Maria, D., Yaari, G., and Kleinstein, S.H. (2015). Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics 31, 3356–3358.

48. Mukherjee, S., Sirohi, D., Dowd, K.A., Chen, Z., Diamond, M.S., Kuhn, R.J., and Pierson, T.C. (2016). Enhancing dengue virus maturation using a stable furin over-expressing cell line. Virology 497, 33–40.

49. Scobey, T., Yount, B.L., Sims, A.C., Donaldson, E.F., Agnihotram, S.S., Menachery, V.D., Graham, R.L., Swanstrom, J., Bove, P.F., Kim, J.D., et al. (2013). Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci 110, 16157–16162.

50. Yount, B., Curtis, K.M., Fritz, E.A., Hensley, L.E., Jahrling, P.B., Prentice, E., Denison, M.R., Geisbert, T.W., and Baric, R.S. (2003). Reverse genetics with a full-length
infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci
100, 12995–13000.

51. Ackerman, M.E., Moldt, B., Wyatt, R.T., Dugast, A.-S., McAndrew, E., Tsoukas, S., Jost,
S., Berger, C.T., Sciaranghella, G., Liu, Q., et al. (2011). A robust, high-throughput
assay to determine the phagocytic activity of clinical antibody samples. Journal of
Immunological Methods 366, 8–19.

52. Fischinger, S., Fallon, J.K., Michell, A.R., Broge, T., Suscovich, T.J., Streeck, H., and
Alter, G. (2019). A high-throughput, bead-based, antigen-specific assay to assess the
ability of antibodies to induce complement activation. Journal of Immunological Methods
473, 112630.

53. Madeira, F., Park, Y. mi, Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P.,
Tivey, A.R.N., Potter, S.C., Finn, R.D., et al. (2019). The EMBL-EBI search and
sequence analysis tools APIs in 2019. Nucleic Acids Research 47, W636–W641.

54. Henikoff, S., and Henikoff, J.G. (1992). Amino acid substitution matrices from protein
blocks. Proc Natl Acad Sci 89, 10915–10919.

55. Baca, M., Presta, L.G., O'Connor, S.J., and Wells, J.A. (1997). Antibody Humanization
Using Monovalent Phage Display. Journal of Biological Chemistry 272, 10678–10684.

56. Walls, A.C., Xiong, X., Park, Y.-J., Tortorici, M.A., Snijder, J., Quispe, J., Cameroni, E.,
Gopal, R., Dai, M., Lanzavecchia, A., et al. (2019). Unexpected Receptor Functional
Mimicry Elucidates Activation of Coronavirus Fusion. Cell 176, 1026-1039.e15.

57. Tang, X.-C., Agnihotram, S.S., Jiao, Y., Stanhope, J., Graham, R.L., Peterson, E.C.,
Avnr, Y., Tallarico, A.S.C., Sheehan, J., Zhu, Q., et al. (2014). Identification of human
neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.
Proceedings of the National Academy of Sciences 111, E2018–E2026.
Highlights and eTOC blurb

Highlights

- Applied LIBRA-seq to PBMCs from a recovered SARS-CoV donor
- Identified six cross-reactive CoV mAbs that target distinct domains on SARS-CoV-2 spike
- Characterized mAbs with effector functions in SARS-CoV-2 murine infection model

eTOC blurb

Shiakolas et al. demonstrate that cross-reactive coronavirus antibodies induced by natural infection display a spectrum of epitope specificities across the spike protein and exhibit \textit{in vitro} and \textit{in vivo} anti-viral functions.
Figure 1

A) Antigen Screening Library

B) Cellular Input

C) ELISA AUC

D) SARS-CoV-2 LIBRA-seq Score vs. SARS-CoV S LIBRA-seq Score

- SARS-CoV-2 S
- SARS-CoV S
- HCoV-OC43
- HCoV-HKU1
- SARS-CoV-2 HexaPro S
- 46472-1
- 46472-2
- 46472-3
- 46472-4
- 46472-6
- 46472-12
- VRC01
- 240CD

E) ELISA AUC

- min
- max
Figure 2

A

| SARS-CoV-2 S1 | SARS-CoV-2 S1 D614G | SARS-CoV-2 S2 | SARS-CoV-2 HP Spike |
|---------------|---------------------|---------------|--------------------|
| 46472-1       | 46472-2             | 46472-3       | 46472-4            |
| 46472-6       | 46472-12            | VRC01         | 240CD              |

B

| SARS-CoV-2 RBD | SARS-CoV RBD | SARS-CoV-2 NTD | SARS-CoV-2 HP Spike |
|----------------|--------------|----------------|--------------------|
| 46472-6        | 46472-12     | anti-VEGF      | 240CD              |
|                |              |                | CR3022             |

C

D

| SARS-CoV-2 | 46472-1 | 46472-2 | 46472-3 | 46472-4 | 46472-6 | 46472-12 | Negative |
|------------|---------|---------|---------|---------|---------|----------|----------|
| 46472-1    | 91      | 102     | -2      | 3       | 2       | 9        | 1        |
| 46472-2    | 50      | 96      | 58      | 8       | 7       | 6        | 8        |
| 46472-3    | 57      | 41      | 99      | 0       | -13     | 8        | 0        |
| 46472-4    | -12     | -10     | -9      | 94      | -2      | 6        | 0        |
| 46472-6    | -11     | -3      | -2      | 84      | 3       | 7        | 0        |
| 46472-12   | 24      | -2      | -2      | 22      | 8       | 0.70     | 0        |

| SARS-CoV   | 46472-1 | 46472-2 | 46472-3 | 46472-4 | 46472-6 | 46472-12 | Negative |
|------------|---------|---------|---------|---------|---------|----------|----------|
| 46472-1    | 93      | 83      | -4      | 3       | 8       | 3        | -13      |
| 46472-2    | 51      | 97      | 75      | 1       | 1       | 1        | -2       |
| 46472-3    | 64      | 39      | 97      | -5      | 4       | 6        | 6        |
| 46472-4    | 21      | 5       | -2      | 82      | 9       | 9        | 7        |
| 46472-6    | 5       | 0       | 0       | 2       | 90      | 11       | 1        |
| 46472-12   | 13      | 6       | 4       | 4       | 2       | 91       | 1        |

E

| Working Concentration (µg/ml) | 46472-1 | 46472-2 | 46472-3 |
|------------------------------|---------|---------|---------|
| ELISA AUC                    |         |         |         |

F

NTD 46472-12

RBD 46472-6
Figure 3

A. SARS-CoV-2 S

B. SARS-CoV S

C. SARS-CoV-2 S

D. SARS-CoV-2 S
A

n=4 or 5

Weight Measurement

Day-1

200 μg 1x10^3 or 1x10^4 PFU mAb i.p. SARS-CoV-2 MA

Tissue Collection

B

SARS-CoV-2 MA 10^3 PFU

% Starting body weight

Days Post Infection

C

SARS-CoV-2 MA 10^4 PFU

% Starting body weight

Days Post Infection

D

Survival [%]

Days Post Infection